Dow Jones -- While Eugene Melnyk has been funding his latest venture, Trimel BioPharma, mostly on his own, the company he started from scratch will consider other financing options this year, including an initial public offering.
Dow Jones -- While Eugene Melnyk has been funding his latest venture, Trimel BioPharma, mostly on his own, the company he started from scratch will consider other financing options this year, including an initial public offering.
